PDT 99 - $3.5M - Seed - Feel Therapeutics.pdf
- 2. 1 out of 4 of us will experience a mental disorder1 Mental illness will be the leading cause of disability by 20301 costing $6 Trillion Sources: 1WHO Global burden of disease, 2ncbi.nlm.nih.gov/pmc/articles/PMC4392551 >45% of patients with chronic conditions struggle with behavioral health2
- 3. THERMOMETER STETHOSCOPE BLOOD PRESSURE MONITOR GLUCOSE METER MENTAL HEALTH ? EVERY OTHER MEDICAL PRACTICE USES OBJECTIVE MEASUREMENT TOOLS No objective monitoring for mental health PROBLEM
- 4. TECHNOLOGY Feel’s proprietary Digital Precision Medicine Platform brings continuous and passive monitoring to mental health. MOOD MENTAL STRESS SLEEP PHYSICAL SYMPTOMS SOCIAL ACTIVITY PSYCHOMOTOR ACTIVITY COGNITIVE FUNCTIONING PSYCHOPHYSIOLOGICAL MONITORING Digital Biomarkers Proprietary Algorithms Continuous Monitoring Wearable Devices Sensors of the Mobile Phone Voice, Video & Text VITALS PHYSICAL ACTIVITY BODY ENERGY
- 5. 1. REMOTE MONITORING DEVICE & APP 2. PROPRIETARY ALGORITHMS 3. REAL-TIME SUPPORT & ADHERENCE TOOLS 5. DIGITAL CBT PROGRAM & PSYCHO- EDUCATION 4. CLINICIAN’S DASHBOARD & COACHING Sleep Physical & psychomotor activity Stress Emotions Social activity SOLUTION | LINKING REMOTE MONITORING WITH PRECISE INTERVENTION 24/7/365 6. MEDICATION
- 6. IMPACT TO PATIENTS ACROSS MENTAL HEALTH CONDITIONS MDD Countries: 5 Subjects: 817 Total countries 9 Total Patients 2,727 23 Research & clinical studies Active 2018- 2024 PTSD Countries: 1 Subjects: 95 Healthy w/ risk factors Countries: 5 Subjects: 1154 ADHD Countries: 1 Subjects: 100 Eating Disorders Countries: 1 Subjects: 80 MDD GAD PTSD ADHD Eating Disorders Number of studies Healthy w/ risk factors GAD Countries: 5 Subjects: 427 6 THERAPEUTIC AREAS IN CNS 6 TAs PIPELINE (e.g. Oncology, Hematology et al.) *Starting in 2024 MS* Countries: 1 Subjects: 50 5 6 3 7 1 1 1 0 2 4 6 8 MS
- 7. PUBLICATIONS Precision DTx delivers superior improvement in outcomes in depression and/or anxiety Read Publication 87% precision in detecting changes in the mood state of patients in psychiatry Read Publication Psychophysiologi cal index for Stress Emotion Detection 2 Outcomes of Feel DTx for Depression and Anxiety Precision and accuracy of emotional state detection and recognition Psychophysiologi cal index for Stress Resilience Psychophysiologi cal index for Stress strongly correlates with changes in Cortisol levels Read Publication Psychophysiologi cal index for Stress Electrodermal Activity (EDA) can be a stress resilience metric in stressful conditions Read Publication Psychophysiologi cal index for Stress strongly correlates with changes in the Endocannabinoid System Read Publication Precision DTx shows improvement in mental health outcomes for ADHD populations Read Publication Outcomes of Feel DTx for ADHD Digital Biomarker for Detection of ADHD Detection of ADHD utilizing physiological signals from wearables Publication Pending
- 8. PATENTS Patent for detecting changes in the mood state of an individual based on physiological & digital data Patent No: US1141068282 Method for detecting and recognizing an emotional state of a user (Continuation) Patent Granted Depression Relapse Digital Biomarker Emotion Detection 2 Emotion Detection Emotion Detection 2 ADHD Digital Biomarker Method for characterizing, detecting, and monitoring ADHD Patent pending Insomnia Digital Biomarker System and method for characterizing, detecting, and monitoring insomnia Patent pending System and method for characterizing, detecting, and monitoring relapse in depression Patent pending
- 9. STATS TEAM INVESTORS CORE TEAM 800+ TEAM MEMBER PUBLICATIONS 16000+ TEAM MEMBER CITATIONS 9 POST-DOCS IN THE CORE TEAM 4 PROFESSORS OF PSYCHIATRY 31 TEAM MEMBERS IN THE USA & EUROPE $180k CORE GROSS MONTHLY BURN RATE A COMPANY OF: GEORGE ELEFTHERIOU CO-FOUNDER & CEO FORMER MCKINSEY, COLUMBIA SHARON KAPLOW VP OF CLINICAL OPERATIONS, FORMER CLINICAL LEAD AbleTo HARIS TSIRBAS, PhD CO-FOUNDER & CTO PHD IN BIOMEDICAL ENGINEERING LEADERSHIP TEAM INDUSTRY EXPERTS MICHEL VOUNATSOS FORMER CEO OF BIOGEN DR. NIKOS DASKALAKIS PROFESSOR OF PSYCHIATRY AT HARVARD STAYCE BECK FORMER DIRECTOR PERSONALIZED MEDICINE & BIOMARKERS @ FDA PSYCHIATRY EXPERTS DR. PETER YELLOWLEES PROFESSOR OF PSYCHIATRY AT UC DAVIS DR. JOAQUIN ANGUERA PROFESSOR OF PSYCHIATRY AT UCSF TORSTEN OLETZKY FORMER CEO OF ERGO
- 10. EXISTING ROUND MILESTONES FDA approval of our wearable as a 510k class II medical device Launch as a Drug+ in the market & clearance of Feel DTx program as an adjunct to medication PRE-SERIES A FUNDRAISING $1M left in a $3.5M round to reach an inflection point Empatica closed their series B financing from Sanofi after receiving FDA clearance for a similar device Recent FDA clearance of DTx for the Adjunctive Treatment of MDD Terms: Convertible Note with $30M Cap and 20% Discount Closed $2.5M led by expert Neurotech investors (Satori Neuro)
- 11. George Eleftheriou, Co-Founder & CEO 479 Jessie Street, San Fransisco, CA 94103 +1 551 232 1020 | [email protected] | www.feeltherapeutics.com